Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease

A therapeutic vaccine for human Chagas disease is under development by the Sabin Vaccine Institute Product Development Partnership. The aim of the vaccine is to significantly reduce the parasite burden of Trypanosoma cruzi in humans, either as a standalone product or in combination with conventional...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Hum Vaccin Immunother
Main Authors: Seid, Christopher A., Jones, Kathryn M., Pollet, Jeroen, Keegan, Brian, Hudspeth, Elissa, Hammond, Molly, Wei, Junfei, McAtee, C. Patrick, Versteeg, Leroy, Gutierrez, Amanda, Liu, Zhuyun, Zhan, Bin, Respress, Jonathan L., Strych, Ulrich, Bottazzi, Maria Elena, Hotez, Peter J.
Formato: Artigo
Idioma:Inglês
Publicado: Taylor & Francis 2016
Assuntos:
Research Papers
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5360114/
https://ncbi.nlm.nih.gov/pubmed/27737611
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2016.1242540
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares